Jason Q. Tang
Jason Q. Tang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Gianluca Veggiani
Pathobiological Sciences, Louisiana State University, Baton Rouge, United States, USA
3 shared publications C. Chen
The Anvil Institute, Kitchener, Canada
2 shared publications- Gregory D. Martyn
Department of Antibody Engineering, Genentech, South San Francisco, CA, USA
2 shared publications J. Gu
The Anvil Institute, Kitchener, Canada
2 shared publications- Kenneth H. Pearce
Center for Integrative Chemical Biology and Drug Discovery, Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States
2 shared publications - Mackenzie Woestman Krone
Department of Molecular, Cellular, and Developmental Biology
2 shared publications
Latest Publications
- Open Access
Ubiquitin Engineering for Interrogating the Ubiquitin–Proteasome System and Novel Therapeutic Strategies
Protein turnover, a highly regulated process governed by the ubiquitin–proteasome system (UPS), is essential for maintaining cellular homeostasis. Dysregulation of the UPS has been implicated in various diseases, including viral infections and cancer, making the proteins in the UPS attractive targets for therapeutic intervention. However, the functional and structural redundancies of UPS enzymes present challenges in identifying precise drug targets and achieving target selectivity. Consequently, only 26S proteasome inhibitors have successfully advanced to clinical use thus far. To overcome these obstacles, engineered peptides and proteins, particularly engineered ubiquitin, have emerged as promising alternatives. In this review, we examine the impact of engineered ubiquitin on UPS and non-UPS proteins, as well as on viral enzymes. Furthermore, we explore their potential to guide the development of small molecules targeting novel surfaces, thereby expanding the range of druggable targets.
Open AccessUbiquitin Engineering for Interrogating the Ubiquitin–Proteasome System and Novel Therapeutic Strategies
Protein turnover, a highly regulated process governed by the ubiquitin–proteasome system (UPS), is essential for maintaining cellular homeostasis. Dysregulation of the UPS has been implicated in various diseases, including viral infections and cancer, making the proteins in the UPS attractive targets for therapeutic intervention. However, the functional and structural redundancies of UPS enzymes present challenges in identifying precise drug targets and achieving target selectivity. Consequently, only 26S proteasome inhibitors have successfully advanced to clinical use thus far. To overcome these obstacles, engineered peptides and proteins, particularly engineered ubiquitin, have emerged as promising alternatives. In this review, we examine the impact of engineered ubiquitin on UPS and non-UPS proteins, as well as on viral enzymes. Furthermore, we explore their potential to guide the development of small molecules targeting novel surfaces, thereby expanding the range of druggable targets.
- Open Access
- 30 November 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1
Author Correction: High-affinity chromodomains engineered for improved detection of histone methylation and enhanced CRISPR-based gene repression
- 30 November 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1
Open AccessAuthor Correction: High-affinity chromodomains engineered for improved detection of histone methylation and enhanced CRISPR-based gene repression
- Open Access
- 15 November 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
High-affinity chromodomains engineered for improved detection of histone methylation and enhanced CRISPR-based gene repression
Histone methylation is an important post-translational modification that plays a crucial role in regulating cellular functions, and its dysregulation is implicated in cancer and developmental defects. Therefore, systematic characterization of histone methylation is necessary to elucidate complex biological processes, identify biomarkers, and ultimately, enable drug discovery. Studying histone methylation relies on the use of antibodies, but these suffer from lot-to-lot variation, are costly, and cannot be used in live cells. Chromatin-modification reader domains are potential affinity reagents for methylated histones, but their application is limited by their modest affinities. We used phage display to identify key residues that greatly enhance the affinities of Cbx chromodomains for methylated histone marks and develop a general strategy for enhancing the affinity of chromodomains of the human Cbx protein family. Our strategy allows us to develop powerful probes for genome-wide binding analysis and live-cell imaging. Furthermore, we use optimized chromodomains to develop extremely potent CRISPR-based repressors for tailored gene silencing. Our results highlight the power of engineered chromodomains for analyzing protein interaction networks involving chromatin and represent a modular platform for efficient gene silencing.
- 15 November 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
Open AccessHigh-affinity chromodomains engineered for improved detection of histone methylation and enhanced CRISPR-based gene repression
Histone methylation is an important post-translational modification that plays a crucial role in regulating cellular functions, and its dysregulation is implicated in cancer and developmental defects. Therefore, systematic characterization of histone methylation is necessary to elucidate complex biological processes, identify biomarkers, and ultimately, enable drug discovery. Studying histone methylation relies on the use of antibodies, but these suffer from lot-to-lot variation, are costly, and cannot be used in live cells. Chromatin-modification reader domains are potential affinity reagents for methylated histones, but their application is limited by their modest affinities. We used phage display to identify key residues that greatly enhance the affinities of Cbx chromodomains for methylated histone marks and develop a general strategy for enhancing the affinity of chromodomains of the human Cbx protein family. Our strategy allows us to develop powerful probes for genome-wide binding analysis and live-cell imaging. Furthermore, we use optimized chromodomains to develop extremely potent CRISPR-based repressors for tailored gene silencing. Our results highlight the power of engineered chromodomains for analyzing protein interaction networks involving chromatin and represent a modular platform for efficient gene silencing.